Radial Artery OcclusionEASY-HeparinNCT06981624
Comparison of the Systematic Versus the Selective Use of Heparin for the Prevention of Radial Artery Occlusion
A study testing No heparin in people with Radial Artery Occlusion, run by Olivier F. Bertrand at 1 site in Canada.
Trial summary
Randomized study comparing the systematic use of heparin (standard of care) against an elective use of heparin to prevent radial artery occlusion after a percutaneous catheterization using a dual-artery compression system. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Radial Artery Occlusion
- What is being tested?
- No heparin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteCanada
- Study dates
- 13 May 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Any patient referred for a diagnostic transradial catheterism
Who cannot join
- Unable to understand study design or provide informed consent
- Unable to receive antiplatelet therapy with aspirina and/or clopidogrel-prasugrel and/or ticagrelor and intravenous anticoagulant derived from heparine or bivalirudine
- Local condition such as hematoma or pseudo-aneurims precluding radial or ulnar access.
- Presence of plethysmographic waveform with simultaneous radial and ulnar occlusive compression (due to colaterals or interouseous artery) precluding the evaluation of patent hemostasis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
IUCPQ
Québec, Quebec, G1V4G5
Michele Jadin, 4186568711, michele.jadin@criucpq.ulaval.ca
About this study
Official title: Comparaison d'un Traitement systématique à l'héparine Versus sélectif Pour la prévention de l'Occlusion Radiale EASY-Héparine
Randomized study comparing the systematic use of heparin (standard of care) against an elective use of heparin to prevent radial artery occlusion after a percutaneous catheterization using a dual-artery compression system.
- Conditions
- Radial Artery Occlusion
- Being tested
- No heparin
- Medical subject headings
- Arterial Occlusive Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No heparinOther
Hemostasis achieved using a dual-artery compression device without administration of heparin after trans-radial diagnostic catheterization
| Study group | Role | What they receive |
|---|---|---|
| Heparin | No intervention | Standard of care with 70-100 IU/kg of heparin after a diagnostic only trans-radial catheterization and a dual-artery compression device for hemostasis. |
| No heparin | Experimental | No heparin administered after diagnostic only trans-radial catheterization and a dual-artery compression device for hemostasis. Receives: Other: No heparin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rates of patent hemostasis
Evaluation of patent hemostasis by pulse oximetry
Measured: within 24 hours after diagnostic angiography
Time to hemostasis
Measured: within 24 hours post-procedure
Nursing time involvement
Calculation of nursing time required for surveillance and care of hemostasis
Measured: within 24 hours post-procedure
Evaluation of complications
Compilation of access site complications such as radial artery occlusion, bleeding, presence and grading of hematomas, etc.
Measured: within 30 days of procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2025
- Study start13 May 2025
- Primary completionAug 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Radial Artery OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Olivier F. Bertrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Olivier F. Bertrand, Laval University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06981624
- Sponsor's protocol ID
- EASY-Heparin
- Acronym
- EASY-Heparin
- Status last verified
- May 2025
- First submitted
- 1 May 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparaison d'un Traitement systématique à l'héparine Versus sélectif Pour la prévention de l'Occlusion Radiale EASY-Héparine
- ClinicalTrials.gov ID
- NCT06981624
- Acronym / sponsor ID
- EASY-Heparin / EASY-Heparin
- Conditions
- Radial Artery Occlusion
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Olivier F. BertrandUniversity, hospital or other
- Study start
- 13 May 2025 (actual)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 21 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Randomized study comparing the systematic use of heparin (standard of care) against an elective use of heparin to prevent radial artery occlusion after a percutaneous catheterization using a dual-artery compression system.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Heparin | No intervention | –Standard of care with 70-100 IU/kg of heparin after a diagnostic only trans-radial catheterization and a dual-artery compression device for hemostasis. |
| No heparin | Experimental | Other: No heparinNo heparin administered after diagnostic only trans-radial catheterization and a dual-artery compression device for hemostasis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Any patient referred for a diagnostic transradial catheterism
Key exclusion criteria (4 listed)
- Unable to understand study design or provide informed consent
- Unable to receive antiplatelet therapy with aspirina and/or clopidogrel-prasugrel and/or ticagrelor and intravenous anticoagulant derived from heparine or bivalirudine
- Local condition such as hematoma or pseudo-aneurims precluding radial or ulnar access.
- Presence of plethysmographic waveform with simultaneous radial and ulnar occlusive compression (due to colaterals or interouseous artery) precluding the evaluation of patent hemostasis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No heparinHemostasis achieved using a dual-artery compression device without administration of heparin after trans-radial diagnostic catheterization | Other | No heparin |
Primary outcome
Rates of patent hemostasis
Time frame: within 24 hours after diagnostic angiography
Evaluation of patent hemostasis by pulse oximetry
Time to hemostasis
Time frame: within 24 hours post-procedure
Nursing time involvement
Time frame: within 24 hours post-procedure
Calculation of nursing time required for surveillance and care of hemostasis
Evaluation of complications
Time frame: within 30 days of procedure
Compilation of access site complications such as radial artery occlusion, bleeding, presence and grading of hematomas, etc.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
Related trials for Radial Artery Occlusion
Not yet recruitingPhase 4
SPARK Study - Sympathetic Periarterial Radial Block in Healthy Volunteers
Healthy Volunteers, Sympathetic Activity
Recruiting
DIStal Versus COnventional Radial Access for COMPLEX Large-bore Percutaneous Coronary Intervention
Vascular Access Site Occlusion
Recruiting
Randomization of Single vs Multiple Arterial Grafts
Coronary Artery Disease, Heart Diseases
RecruitingObservational study
Radial Access Data in Vascular Interventions Registry
Radial Artery Occlusion, Radial Artery Spasm
Recruiting
Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)
Coronary Angiography, Percutaneous Coronary Intervention
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing No heparin in people with Radial Artery Occlusion, run by Olivier F. Bertrand at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michele Jadin (418-656-8711, michele.jadin@criucpq.ulaval.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rates of patent hemostasis (time frame: within 24 hours after diagnostic angiography). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.